WILMINGTON, Del.--(BUSINESS WIRE)--Results from a post-hoc exploratory subgroup analysis from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab), administered perioperatively in ...

The Company has analyzed the preliminary immune response data from FLAMINGO-01. Immune response data in both the HLA-A*02 treated and placebo arms and the third open label arm with all other HLA types ...

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma Patients were randomly assigned to receive I-DXd 8 ...

GH Research PLC has provided updates on its GH001 treatment for depression, reporting completion of the Open-Label Extension analysis that shows a 73% remission rate at six months without serious ...

ORLANDO, Fla. — Up to half of all people with severe chronic hand eczema (CHE) who apply delgocitinib cream (Anzupgo) to their hands twice a day have had a profound response to treatment, and about a ...